Table 1 Clinical and hematologic... | American Society of Hematology

Table 1

Clinical and hematologic features of patients with MDS without excess blasts classified according to the unsupervised clustering analysis including WHO classification criteria and mutation pattern

Clinical variables	MDS associated with SF3B1 mutation	MDS NOS	MDS with MD-associated mutations*
No. of patients	51	55	51
Age (years)	69 (46-88)	67 (29-88)	71 (45-88)
Sex (male/female)	24/27	27/28	32/19
WHO category
RA	3	22	3
RARS	31	2	1
RCMD	1	26	40
RCMD-RS	16	5	7
Hemoglobin (g/dL)	9.4 (6.9-12.8)	9.5 (6.5-13.9)	9.2 (6.1-12.9)
WBC count (×10⁹/L)	5.1 (1.4-9.3)	3.9 (1.18-10.6)	3.4 (0.6-11.1)
ANC† (×10⁹/L)	2.7 (0.8-7.5)	2.0 (0.1-7.6)	1.5 (0.1-7.8)
Platelets (×10⁹/L)	247 (16-536)	98 (5-434)	111 (7-315)
BM blasts (%)	1 (0-4)	2 (0-4)	3 (1-4)
RS (%)	65 (2-95)	0 (0-77)	0 (0-62)
Karyotype (IPSS-R)
Very good	2	2	—
Good	38	39	37
Intermediate	5	6	6
High	1	4	3
Very high	—	1	—
Failed	5	3	5
No. of mutations	2 (1-9)	1 (0-5)	3 (1-7)

Clinical variables	MDS associated with SF3B1 mutation	MDS NOS	MDS with MD-associated mutations*
No. of patients	51	55	51
Age (years)	69 (46-88)	67 (29-88)	71 (45-88)
Sex (male/female)	24/27	27/28	32/19
WHO category
RA	3	22	3
RARS	31	2	1
RCMD	1	26	40
RCMD-RS	16	5	7
Hemoglobin (g/dL)	9.4 (6.9-12.8)	9.5 (6.5-13.9)	9.2 (6.1-12.9)
WBC count (×10⁹/L)	5.1 (1.4-9.3)	3.9 (1.18-10.6)	3.4 (0.6-11.1)
ANC† (×10⁹/L)	2.7 (0.8-7.5)	2.0 (0.1-7.6)	1.5 (0.1-7.8)
Platelets (×10⁹/L)	247 (16-536)	98 (5-434)	111 (7-315)
BM blasts (%)	1 (0-4)	2 (0-4)	3 (1-4)
RS (%)	65 (2-95)	0 (0-77)	0 (0-62)
Karyotype (IPSS-R)
Very good	2	2	—
Good	38	39	37
Intermediate	5	6	6
High	1	4	3
Very high	—	1	—
Failed	5	3	5
No. of mutations	2 (1-9)	1 (0-5)	3 (1-7)

IPSS-R, revised international prognostic scoring system; WBC, white blood cell.

MD-associated mutations: DNA methylation, splicing factors other than SF3B1, RAS pathway, and cohesin complex.

†

ANC indicates absolute neutrophil count.

View Large

This Feature Is Available To Subscribers Only